ImmunityBio (IBRX) Change in Accured Expenses (2014 - 2026)

ImmunityBio (IBRX) has reported Change in Accured Expenses for 13 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 124.26% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $19.3 million (up 448.55% YoY), while the FY2025 annual figure was $3.2 million, up 311.14% from the prior year.
• Change in Accured Expenses climbed to $3.1 million in Q1 2026 per IBRX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $18.6 million in Q1 2023 and bottomed at -$19.5 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged $917882.4 across 5 years, with a median of $3.1 million in 2026.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 675.33% — and 2023, when it plunged 519.36%.
• ImmunityBio's Change in Accured Expenses stood at -$3.2 million in 2022, then slumped by 519.36% to -$19.5 million in 2023, then surged by 89.17% to -$2.1 million in 2024, then jumped by 191.06% to $1.9 million in 2025, then jumped by 62.96% to $3.1 million in 2026.
• Business Quant data shows IBRX's Change in Accured Expenses at $3.1 million in Q1 2026, $1.9 million in Q4 2025, and $5.5 million in Q3 2025.